Cogent Biosciences, Inc. (NasdaqGS: COGT)
Health Care · Biotechnology · US
$36.80
0.00% today · +212.1% 1Y
Cogent Biosciences, Inc. (NasdaqGS: COGT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.39B and employs 258 people.
Over the last twelve months the share price has gained 212.1%, trading between 11.53 and 43.73.
Tweenvest scores Cogent Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
COGT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.39B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.43
- Dividend yield
- —
- Beta (5Y)
- 0.33
- 52-week high
- $43.73
- 52-week low
- $11.53
- Avg volume (3M)
- —
- Shares outstanding
- 173.57M
- Employees
- 258
- Next earnings
- —
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
- ISIN
- US19240Q2012
- Listed since
- Mar 29, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.26 | -1.70% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.02 | -0.73% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.48 | -0.87% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.02 | -1.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.08 | -1.02% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.71 | -5.11% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.